Selected Startup Pitches

AGELABS	**Age Labs - Norway - Diagnostics** Age Labs AS is a life science company focused on developing new biomarkers for the early detection of age-related diseases. They analyze epigenetic changes in immune cells to identify patterns that lead up to disease. Their pipeline includes novel precision biomarkers for the early detection of rheumatoid arthritis and severe COVID-19.
AGIANA PHARMACEUTICALS	**Agiana Pharmaceuticals - Norway - Biotech** Agiana Pharmaceuticals is a clinical stage biotech developing a first-in-class anti-arrhythmic therapeutic. Agiana's lead asset, AGP100, is Phase 2 ready and the Phase 1 studies in both healthy adults and elderly did not show any tolerability and safety signals. The company is now raising $18M (Series A) to finance Phase 2A (PoC) in an orphan arrhythmic disease.and the company has in place experienced scientific advisors, board of directors and management team with track record and TA experience.
AKTHELIA PHARMACEUTICALS	**Akthelia Pharmaceuticals - Iceland - Biopharma** Akthelia Pharma is a late preclinical-stage immunotherapy biopharma company, with a breakthrough strategy to upregulate the innate immunology of epithelia. They are looking to raise $11M to fund their lead therapeutic program through IND preparation and Phase I, which aims to improve cancer chemotherapy outcomes, addressing the large unmet need of neutropenic sepsis. This first application of our technology enhances integrity of the GI tract wall to block bacterial leakage of the microbiome, a key source of bloodstream infection.
amplio Pharma	**Amplio Pharma - Sweden - Drug Repurposing** Amplio Pharma is a novel and exciting product company developing improved versions of already great drugs. They are momentarily preparing our first clinical trial application for Methotrexate Forte, an innovative, proprietary candidate drug product for the treatment of rheumatoid arthritis.
ANISON Therapeutics	**Anison Therapeutics - Finland - Biopharma** Anison Therapeutics aims at building a portfolio targeting the eradication of the Human Papillomavirus (HPV)-mediated diseases. The first steps are taken by dedicated efforts towards developing and commercializing a natural medication that addresses unmet medical needs for Genital Warts, with preclinical studies projected to start during the first half of 2023. Longer term, the company will also put focus on the treatment of genital pre-cancerous lesions and other HPV-associated warts including common and foot (plantar) warts, thus becoming a successful company with solid sales growth and a strong pipeline of new products to be introduced to the roughly $8B market.

1-pagers for each company available here

APLEX BIO	**Aplex Bio - Sweden - Deep Tech, Molecular Diagnostics** Aplex Bio is developing a next-generation hyperplex PCR technology powered by its unique nanoprobes, currently being evaluated by partners and early access customers including first paying customers. They now work towards a beta kit release that can be shipped to early testers, scale-up of nanoprobe production, and continued development of our core technology and assays for demonstration in multiple high-value applications including wastewater epidemiology, food/feed testing, pathogen diagnostics, cancer detection and precision diagnostics together with KOL's. With the launch of beta-kits they expect to start generating early sales.
AQSENS®	**Aqsens Health - Finland - Biosensors** Aqsens Health has patented innovations in Enhanced Time Resolved Fluorescence (E-TRF) technology and biosensor development for novel cancer and infectious diseases diagnostics. Aqsens Health biosensors mimic the natural affinity of phages (ie. viruses) to rapidly detect disease-specific biomarkers from urine and saliva. Currently developed prostate cancer and its metastasis biosensors as well as malaria biosensor have proved very sensitive and specific in clinical validation.
arivin	**Arivin Therapeutics - Finland - Drug Development, Therapeutics** Arivin Therapeutics is utilizing novel chemistry to develop molecules that specifically target bacterial virulence factors to treat Gram-negative antibiotic-resistant infections. The virulence inhibitors are effective against World Health Organization top priority pathogens Pseudomonas aeruginosa and Acinetobacter baumannii and reduce inflammatory responses in vitro and in vivo. The treatment avoids rapid resistance build-up, and synergizes with standard-of-care anti-infectives in Cystic Fibrosis and non-CF bronchiectasis.
ARXX THERAPEUTICS	**Arxx Therapeutics - Norway - Biotech** Arxx Therapeutics is a Danish/Norwegian biotech developing effective therapies against fibrosis, with a first-in-class monoclonal antibody to neutralize a target called S100A4, an alarm signal DAMP, positioned upstream of a broad range of pro-inflammatory and pro-fibrotic pathways. As the only biotech exploring this approach, Arxx has produced highly compelling pre-clinical data in collaboration with world-leading experts in fibrosis. The company is nowcommencing a clinical Phase 1, leading to a Phase 2 PoC in systemic sclerosis, a fibrotic disease affecting 140K patients for whom no approved drugs for disease modification exist and thereby have enormous medical need. Systemic sclerosis serves as their first indication and an ideal stepping stone into further fibrotic indications.
asgard THERAPEUTICS	**Asgard Therapeutics - Sweden - Biotech** Asgard Therapeutics AB is a Swedish private biotech company exploring the application of in vivo direct cell reprogramming for cancer immunotherapy. Formed as a spin-off from Lund University, the Company is pioneering a gene delivery approach centered on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.
BLUE WAVE THERAPEUTICS	**Blue Wave Therapeutics - Norway - Therapeutic Biotech** Blue Wave Therapeutics (BWT) is a privately owned Swiss/Norwegian-based biotechnology company, founded in 2021 with the goal to develop treatments aiming at significantly improving survival of cancer patients based on its novel biopolymer-radionuclide targeting platform.

1-pagers for each company available here

CEREBRIU TRANSFORMING RADIOLOGY	**Cerebriu - Denmark - Deep Tech, Digital Health** Cerebriu is automating radiology workflows with AI, starting with MRI for brain diagnostic imaging, empowering radiologists with optimized workflows, and bringing clinical intelligence at the point of imaging. Cerebriu currently collaborates with world's largest MRI manufacturer and is CE-marked.
Tampere University	**Decoderma - Finland - Biotech, Medtech** Decoderma discovered a systemically administered peptide (tCRK) that homes to skin and skin wounds and created a recombinant, multi-functional, therapeutic fusion protein of tCRK peptide and decorin (DCN), a natural transforming growth factor-? (TGF-?) inhibitor and an integral protein of skin. Treatment of lethal skin disease, recessive dystrophic epidermolysis bullosa (RDEB) mice with systemically administered recombinant protein resulted in inhibition of fibrosis formation and TGF-? signaling in the skin and significant improvement in the survival of RDEB mice (more than w. any previously tested therapeutic) indicating the best-in-class position.
DoMore DIAGNOSTICS	**DoMore Diagnostics - Norway - Digital Pathology, Deep Learning** Despite decades with significant efforts in gene sequencing, there is a large medical need for better markers that can predict outcomes to improve personal medicine and increase likelihood of success in drug development. Digital pathology and deep learning are on the verge of a breakthrough in medicine and can meet this need. DoMore Diagnostics is uniquely positioned with protected and scalable technology based on top notch research, and being the first company to obtain CE Mark for a prognostic digital marker.
ENVUE TECHNOLOGIES	**Envue Technologies - Sweden - Deep Tech & Life Science** Envue Technologies empower scientists with a patent-pending solution for disruptive discoveries in Life Science, by providing the next-generation bioanalysis instrument. They are at the forefront to address the scientist's global unmet need for a tool that generates data of tiny biomolecules like proteins, DNA, and RNA. Using a cutting-edge combination of nanotechnology and light we develop an instrument to study biological relevant molecules and nanoparticles without introducing modifications to increase reliability and efficiency.
GO-PEN Affordable insulin pen for all	**Go-Pen - Denmark - Medtech, Impact** GO-Pen ApS is a Danish Medtech startup, founded in 2019 by two experienced business and medtech professionals, with the purpose of creating equal access to good diabetes care for all. Their vision is that all people with diabetes who need insulin have access to an insulin pen they can afford.
IMPLEXION PHARMA	**Implexion Pharma - Sweden - Pharmaceuticals** Implexion uses an innovative and scientifically based approach, based on world-leading research, to treat life-style related diseases by designing pharmaceuticals that target the gut bacteria rather than the human cells. The company is entering lead optimization phase with its first candidate and is seeking financial partners to create a unique microbiome-based pharmaceutical development company.
Kipuwex	**Kipuwex - Finland - IoT Device** Kipuwex is an easy-to-use light-weight IoT device which wirelessly, continuously, and digitally measures a plurality of clinically relevant physiological parameters vital to the assessment of human well-being and disease management. The physiological parameters can be monitored remotely anywhere, at any time, by health care professionals and home users with a mobile or web application. Kipuwex then converts physiological parameters with an algorithm into reliable measurements for healthcare professionals and home users.

1-pagers for each company available here

LAKKA HEALTH	**Lakka Health - Finland - Medical & Wellbeing Devices** LAKKA Health Ltd. is a company specialized in developing innovative solutions for medical and wellbeing devices. LAKKA Health is focusing on scent-based diagnostics.
MACULASER	**Maculaser - Finland - Medtech & Deep tech** Maculaser is a clinical phase medical technology company that develops personalized laser therapy for common retinal diseases. Our technology enables personalized, consistent, and early treatment of central vision, potentially shifting the balance from managing late retinal disease symptoms to truly preventive treatments.
MONCYTE	**Moncyte Moncyte - Finland - Diagnostics** Moncyte have a unique solution that provides insight into the cellular mechanisms underlying cholesterol-lowering drug activity in individual patients for high cholesterol. Their test will help the doctor to determine the optimal and personalized treatment strategy, to determine whether statins are enough or more effective treatment is needed, and skip inefficient trial-and-error approach that can normally take years. In result, patients can achieve their treatment goals faster and reduce cardiovascular risk that can in turn contribute to less morbidity and mortality.
MYOPAX	**MyoPax - Denmark - Biotech, Cell & Gene Therapy** MyoPax is an early clinical stage biotech with sites in Copenhagen (BioInnovation Institute) and Berlin (spin-off Charité University Medicine/Helmholtz Association). In the EU, over 15 million people are affected by untreatable muscle wasting caused by common diseases (e.g. cancer), trauma or genetic mutations and leading to loss of personal autonomy and premature death. Skeletal muscle harbors own stem cells, capable of regenerating muscle until old age. Our USP is a patented technology to produce pure and highly regenerative human muscle stem cell populations and their precise virus-free gene engineering. MyoPax is developing a platform for regenerative stem cell therapies for the targeted treatment of multiple muscle diseases.
NaDeNo	**NaDeNo - Norway - Biotechnology, Drug delivery** NaDeNo is a SINTEF spin-off building on more than a decade of research on a nanotechnology drug delivery platform designed for unleashing the potential of hard-to-deliver hydrophobic small molecule drugs. The lead candidate is a proprietary nanoformulation of cabazitaxel encapsulated in polymeric nanoparticles, supported by strong preclinical safety and efficacy data, for local treatment of cancer metastasis in the peritoneum. NaDeNo aims at offering its proprietary platform technology to pharma and biotech companies in need of overcoming drug delivery hurdles of promising drugs.
nanolyze	**Nanolyze - Sweden - Biotech, Nanoparticle Analysis** Nanolyze is a deep-tech start-up located at the Bio Venture Hub in Gothenburg. They are developing unique solutions for analyzing nanoparticles, which is an emerging field in many biotechnological applications such as drug or vaccine delivery and treatment. Their initial instrument is installed at pilot labs and they are in an intense initial market entry phase with customers in pharmaceutical development and university labs.
oncosyne	**Oncosyne - Norway - Biotech** Oncosyne is a clinical-stage biotech startup developing cutting-edge in vitro diagnostics based on personalized drug screening of patient-derived microtumors. Their vision is to provide diagnostic tools that radically improve the precision and efficacy of cancer drug therapies. They are currently optimizing platform performance with a market access-granting clinical performance study planned for 2023.

1-pagers for each company available here

OPTOCEUTICS	**OptoCeutics - Denmark - Digital Therapeutics (DTx)** Optoceutics is a medical device company who develop, test, and commercialize brain stimulation light technology to non-invasively induce 40 Hz gamma brainwaves, which may lead to disease-modifying therapeutic effects in neurodegenerative and psychological disorders such as Alzheimer's Disease. Current main activities are to continue clinical trials and commercialization efforts. The company started in 2018, and has raised nearly 4 mio Euro since its start.
Ousia Pharma	**Ousia Pharma - Denmark - Biotech** Ousia Pharma is a Danish biotech company focused on the development of novel peptide-drug conjugates for the treatment of metabolic diseases and neurodegenerative disorders. For anti-obesity, Ousia Pharma has developed a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to the brain to drive a potent and sustained weight loss without compromising safety. They are seeking investments that will support the progression to clinical evaluation of our lead candidate.
OXCIA	**Oxcia - Sweden - Biotech** Oxcia AB is developing unique revolutionizing treatments through the innovative use of oxidative DNA damage and DNA Damage response (DDR) processes to treat cancer and inflammation- and fibrotic related diseases. Oxcia has two drug candidates with first-in-class drugs potential. OXC-101 is presently in two on-going clinical phase 1 trials, in advanced solid and hematological cancer patients, respectively, and OXC-201 is in preclinical stage developed as a novel treatment for Idiopathic Pulmonary Fibrosis.
PANCRYOS INSULIN. NATURALLY.	**Pancryos - Denmark - Biotech, Stem Cells** Built on nearly two decades of research and development, Pancryos is a privately held, preclinical stage company founded in 2017 and based in Copenhagen, Denmark. Their mission is to develop a curative cell therapy for Type 1 Diabetes. Safer, more efficacious cells coupled with a more viable, functional, and convenient delivery system are key differentiators for Pancryos when compared to available solutions in the marketplace.
pephexia therapeutics	**Pephexia Therapeutics - Denmark - Biotech** Pephexia Therapeutics is a Danish biotechnology company working with the discovery and development of novel peptide-based pharmacotherapies for an effective and convenient treatment of cachexia, sarcopenia, and related diseases. They are focusing on a dual agonistic peptide for the treatment of cancer cachexia and are in the lead optimization phase.
pharmista TECHNOLOGIES	**Pharmista Technologies - Sweden - Diagnostics, Femtech** Pharmista Technologies are creating breakthroughs in diagnostic device development, utilising a re-usable detection technology with a positive impact on both the environment and the end-user. Their initial focus is on upgrading the pregnancy test through the development of a reusable test device that is easy to interpret, hygienic to use, and 99% accurate at the day of expected menstruation. In turn, this increases convenience-levels, reduces customer spendings on their reproductive health, minimises the risk of misinterpreting the test results, and is beneficial for the environment.
rarity BIOSCIENCE	**Rarity BioScience - Sweden - Diagnostics, Bioscience** Rarity BioScience has developed an ultrasensitive technology for nucleic acid detection in liquid biopsies, meaning that they can detect down to 1 mutation in 100,000 healthy cells, which is up to 100 times more sensitive than current technology. They provide the sensitive tools needed to replace conventional costly and painful tissue biopsies with blood samples to enable early detection of cancer relapse and treatment response.

1-pagers for each company available here

REPLICON HEALTH	**Replicon Health - Finland - Biotech, Deep Tech** Replicon Health Oy has developed a New Active Medicinal Substance (NAS/NCE) that can activate mitochondrial metabolism in humans and in animals without an increase in oxidative stress. After years of successful pretesting, they have now shown in a peer reviewed human study that well tolerated oral doses reduces low grade inflammation already in 4-days, and further that in 3-weeks substantial improvements for certain Block Buster drug indications with unmet medical need can be seen. Their patented molecule formulation can uniquely influence the causes of many chronic disorders, not just alleviate the symptoms.
ResoTher ■ Pharma	**ResoTher Pharma - Denmark - Biotech** ResoTher Pharma is a clinical stage biotech company on a mission to improve patient outcomes in serious and life-threatening cardiovascular disorders such as myocardial infarction, stroke and heart failure. Their peptide drug candidates work by potently inducing resolution of inflammation and are targeted towards in-hospital, critical care indications. Their lead asset, RTP-026, is poised for proof of principle testing in myocardial infarct patients, to commence in Q1 2023.
SACRA THERAPEUTICS	**SACRA Therapeutics - Sweden - Biotech** SACRA Therapeutics is a pioneer in the discovery of novel anticancer strategies by targeting the interplay between major oncogenes and RNA modifiers offering a therapeutic opportunity for difficult to treat solid and haematological cancers. They are now seeking funding for SACRA, a partnership involving experts in drug development, clinical oncology, and RNA Epitranscriptomics, in order to advance through the preclinical stages and achieve human proof of concept. Despite being an early-stage company, their focus is "having the end in mind"- being guided by what brings benefits to the patients, at the same time realizing the potential of a novel therapeutic paradigm.
SARTAR Therapeutics	**Sartar Therapeutics - Finland - Biotech, Therapeutics** Sartar develops a first-in-class targeted therapy for Soft Tissue Sarcomas, orphan cancers with high unmet medical need. Their approach is based on the discovery of phosphodiesterase 3 (PDE3) enzymes as novel oncogenes and repositioning of anagrelide with a unique long-acting formulation.
SENSE BIOPHARMA	**Sense Biopharma - Norway - Biotech, RNA Technology** Sense Biopharma is developing novel RNA-based drugs for the treatment of cancer and autoimmune diseases. Their first indication is glioblastoma, an aggressive brain cancer with a high unmet medical need and a 5-year life expectancy at diagnosis of only 5%. Glioblastoma is an orphan indication with an incidence of 12,000/yr in the U.S. and of 300/yr in Norway. The blood-brain barrier is degraded in glioblastomas, thus making the intravenous administration route possible in most patients.
SONAI	**Sonai Health - Finland - Medtech, Diagnostics** Sonai is re-inventing heart diagnostics. They utilize patented sensor technology, cloud service and machine learning to bring special care diagnostics into primary care. The Team has strong knowledge in scientific innovations, medicine and business.
TEITUR TROPHICS	**Teitur Trophics - Denmark - Biotech, Life Science** From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders including Huntington's Disease, Parkinson's Disease and Frontotemporal Dementia. Via subcutaneous delivery, the peptide has shown in vivo PoC across different models and is ready for IND development. Teitur is currently in discussions with investors to set up a syndicate that can support this program to PoC in humans.
TETRAKIT TECHNOLOGIES	**TetraKit Technologies - Denmark - Theranostics, Radiopharmaceuticals** TetraKit Technologies develops next generation of radioactive drugs using its patented labeling platform. This platform can radiolabel small molecules, peptides and antibodies instantly with any radionuclide, for example the best radionuclide pair for molecular imaging and targeted alpha-radionuclide therapy – fluorine-18 and astatine-211. TetraKit is validating the platform technology with superior theranostic drugs for neuroendocrine tumors, and establishes partnerships on a variety of other cancers such as pancreatic and colon cancers.

1-pagers for each company available here

REPLICON HEALTH	**Replicon Health - Finland - Biotech, Deep Tech** Replicon Health Oy has developed a New Active Medicinal Substance (NAS/NCE) that can activate mitochondrial metabolism in humans and in animals without an increase in oxidative stress. After years of successful pretesting, they have now shown in a peer reviewed human study that well tolerated oral doses reduces low grade inflammation already in 4-days, and further that in 3-weeks substantial improvements for certain Block Buster drug indications with unmet medical need can be seen. Their patented molecule formulation can uniquely influence the causes of many chronic disorders, not just alleviate the symptoms.
ResoTher ■ Pharma	**ResoTher Pharma - Denmark - Biotech** ResoTher Pharma is a clinical stage biotech company on a mission to improve patient outcomes in serious and life-threatening cardiovascular disorders such as myocardial infarction, stroke and heart failure. Their peptide drug candidates work by potently inducing resolution of inflammation and are targeted towards in-hospital, critical care indications. Their lead asset, RTP-026, is poised for proof of principle testing in myocardial infarct patients, to commence in Q1 2023.
SACRA THERAPEUTICS	**SACRA Therapeutics - Sweden - Biotech** SACRA Therapeutics is a pioneer in the discovery of novel anticancer strategies by targeting the interplay between major oncogenes and RNA modifiers offering a therapeutic opportunity for difficult to treat solid and haematological cancers. They are now seeking funding for SACRA, a partnership involving experts in drug development, clinical oncology, and RNA Epitranscriptomics, in order to advance through the preclinical stages and achieve human proof of concept. Despite being an early-stage company, their focus is "having the end in mind"- being guided by what brings benefits to the patients, at the same time realizing the potential of a novel therapeutic paradigm.
SARTAR Therapeutics	**Sartar Therapeutics - Finland - Biotech, Therapeutics** Sartar develops a first-in-class targeted therapy for Soft Tissue Sarcomas, orphan cancers with high unmet medical need. Their approach is based on the discovery of phosphodiesterase 3 (PDE3) enzymes as novel oncogenes and repositioning of anagrelide with a unique long-acting formulation.
SENSE BIOPHARMA	**Sense Biopharma - Norway - Biotech, RNA Technology** Sense Biopharma is developing novel RNA-based drugs for the treatment of cancer and autoimmune diseases. Their first indication is glioblastoma, an aggressive brain cancer with a high unmet medical need and a 5-year life expectancy at diagnosis of only 5%. Glioblastoma is an orphan indication with an incidence of 12,000/yr in the U.S. and of 300/yr in Norway. The blood-brain barrier is degraded in glioblastomas, thus making the intravenous administration route possible in most patients.
SONAI	**Sonai Health - Finland - Medtech, Diagnostics** Sonai is re-inventing heart diagnostics. They utilize patented sensor technology, cloud service and machine learning to bring special care diagnostics into primary care. The Team has strong knowledge in scientific innovations, medicine and business.
TEITUR TROPHICS	**Teitur Trophics - Denmark - Biotech, Life Science** From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders including Huntington's Disease, Parkinson's Disease and Frontotemporal Dementia. Via subcutaneous delivery, the peptide has shown in vivo PoC across different models and is ready for IND development. Teitur is currently in discussions with investors to set up a syndicate that can support this program to PoC in humans.
TETRAKIT TECHNOLOGIES	**TetraKit Technologies - Denmark - Theranostics, Radiopharmaceuticals** TetraKit Technologies develops next generation of radioactive drugs using its patented labeling platform. This platform can radiolabel small molecules, peptides and antibodies instantly with any radionuclide, for example the best radionuclide pair for molecular imaging and targeted alpha-radionuclide therapy – fluorine-18 and astatine-211. TetraKit is validating the platform technology with superior theranostic drugs for neuroendocrine tumors, and establishes partnerships on a variety of other cancers such as pancreatic and colon cancers.

1-pagers for each company available here